Brought to you by 
Third Rock contributes to Neon Therapeutics' $55mm Series A round
02 Oct 2015
Executive Summary
Neon Therapeutics (neoantigen-based cancer therapies) raised $55mm through its Series A round, which included investments from Third Rock Ventures, Clal Biotechnology Industries, and Access Industries.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Third Rock contributes to Neon Therapeutics' $55mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice